ProCE Banner Activity

Expert Perspective on the Top Hematologic Malignancy Studies From the 2016 Clinical Oncology Meeting

Conference Coverage
Clinical Thought
Here are expert thoughts on the hematologic malignancies abstracts from ASCO 2016 that have the most potential to change clinical practice.

Released: May 31, 2016

Expiration: May 30, 2017

No longer available for credit.

Share

Faculty

Shaji K. Kumar

Shaji K. Kumar, MD

Mark and Judy Mullins Professor of Hematological Malignancies
Chair, Myeloma Amyloidosis Dysproteinemia Group
Consultant, Division of Hematology
Mayo Clinic
Rochester, Minnesota

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

Amgen, Inc.

Ariad

Bayer Healthcare Pharma

Celgene

Genentech Roche Virology

Incyte

Merck Oncology

Taiho Pharmaceuticals

Faculty Disclosure

Primary Author

Shaji K. Kumar, MD

Mark and Judy Mullins Professor of Hematological Malignancies
Chair, Myeloma Amyloidosis Dysproteinemia Group
Consultant, Division of Hematology
Mayo Clinic
Rochester, Minnesota

Shaji Kumar, MD, has disclosed that he has received funds for contracted research from Celgene, Janssen, Merck, Novartis, Sanofi, and Takeda; and has served as a consultant for Kesios, Noxxon, and Skyline.